Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitors

References

• IMS. Market Research prescription data. 2002
   Google Scholar
• Brookmeyer R, Corrada MM, Curriero FC, et al. Survival following a diagnosis of Alzheimer disease. Arch Neurol 2002;59:1764–7
   PubMed Web of Science ®Google Scholar
• Fava M. Management of non-response and intolerance: switching strategies. J Clin Psychiatry 2000;61(Suppl 2):10–12
   PubMed Web of Science ®Google Scholar
• Stark S, Spierings EL, McNeal S, et al. Naratriptan efficacy in migraineurs who respond poorly to oral sumatriptan. Headache 2000;40:513–20
   PubMed Web of Science ®Google Scholar
• Edwards K, Goodman W, Khoury K, et al. Rapid changeover from donepezil to rivastigmine well tolerated. J Am Geriatr Soc 2001;49:S91–2
   PubMed Web of Science ®Google Scholar
• Farlow MR. Pharmacokinetic profiles of current therapies for Alzheimer’s disease: implications for switching to galantamine. Clin Ther 2001;23(Suppl A):A13–24
   PubMed Web of Science ®Google Scholar
• Farlow M, Etemad B, Auriacombe S, et al. Rationale, benefits and guidelines for switching to rivastigmine. Poster presented at 13th International Congress for Alzheimer’s Disease and Related Disorders (ICADRD), Stockholm, Sweden, July 20–25 2002
   Google Scholar
• Bullock R, Connolly C. Switching cholinesterase inhibitor therapy in Alzheimer’s disease – donepezil to rivastigmine. Int J Geriatric Psychiatry 2002;17:288–9
   PubMed Web of Science ®Google Scholar
• Emre M. Switching cholinesterase inhibitors in patients with Alzheimer’s disease. Int J Clin Pract Suppl 2002;127:64–72
   PubMedGoogle Scholar
• Shua-Haim JR, Smith JM, Amin S. Results of switching from donepezil to rivastigmine in Alzheimer’s disease: a 2-month prospective study. Poster presented at the 7th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy, Geneva, Switzerland, April 3–6 2002
   Google Scholar
• Enz A, Amstutz R, Boddeke H, et al. Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer’s disease. Progr Brain Res 1993;91:431–8
   Google Scholar
• Weinstock M. Selectivity of cholinesterase inhibition. Drugs 1999;12:307–23
   Google Scholar
• Perry E, Perry R, Blessed G, et al. Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol 1978;4:273–7
   PubMed Web of Science ®Google Scholar
• Arendt T, Bruckner M, Lange M, et al. Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer’s disease resemble embryonic development – a study of molecular forms. Neurochem Int 1992;21:381–96
   PubMed Web of Science ®Google Scholar
• Scali C, Casamenti F, Bellucci A, et al. Effect of subchronic administration of metrifonate, rivastigmine and donepezil on brain acetylcholine in aged F344 rats. J Neural Trans 2002;109:1067–80
   PubMed Web of Science ®Google Scholar
• Darreh-Shori T, Almkvist O, Guan ZZ, et al. Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months. Neurology 2002;59: 563–72
   PubMed Web of Science ®Google Scholar
• Giacobini E, Spiegel R, Enz A, et al. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer’s disease by rivastigmine: correlation with cognitive benefit. J Neural Trans 2002;109:1053–65
   PubMed Web of Science ®Google Scholar
• Amici S, Lanari A, Romani R, et al. Cerebrospinal fluid acetylcholinesterase activity after long-term treatment with donepezil and rivastigmine. Mech Ageing Dev 2001;122:2057–62
   PubMed Web of Science ®Google Scholar
• Davidsson P, Blennow K, Andreasen N, et al. Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer’s disease. Neurosci Lett 2001;300:157–60
   PubMed Web of Science ®Google Scholar
• Parnetti L, Amici S, Lanari A, et al. Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors. Neurol Sci 2002;23(Suppl 2):S95–6
   PubMed Web of Science ®Google Scholar
• Samochocki M, Zerlin M, Jostock R, et al. Galantamine is an allosterically potentiating ligand. Acta Neurol Scand Suppl 2000;176:68–73
   PubMedGoogle Scholar
• Samochocki M, Hoffle A, Fehrenbacher A, et al. Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J Pharmacol Exp Ther 2003;305:1024–36
   PubMed Web of Science ®Google Scholar
• Auriacombe S, Pere J-J, Loria-Kanza Y, et al. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease who failed to benefit from treatment with donepezil. Curr Med Res Opin 2002;18:129–38
   PubMed Web of Science ®Google Scholar
• Morris JC. Therapeutic continuity in Alzheimer’s disease: switching patients to galantamine. Clin Ther 2001;23(Suppl A):A1–2
   PubMed Web of Science ®Google Scholar
• Robillard A, Arts SR, Nasreddine Z, et al. Clinically meaningful treatment responses with galantamine in ‘non-responders’ to donepezil treatment. Poster presented at the 10th Congress of the International Psychogeriatric Association (IPA), Nice, France, September 9–14, 2001
   Google Scholar
• Mintzer J, Yuan W, Kershaw P, written communication 2000. In: Ferris SH. Switching previous therapies for Alzheimer’s disease to galantamine. Clin Ther 2001;2(Suppl A):A3–7
   Google Scholar
• Rasmusen L, Yan B, Robillard A, et al. Effects of washout and dose-escalation periods on the efficacy, safety and tolerability of galantamine in patients previously treated with donepezil: ongoing clinical trials. Clin Ther 2001;23(Suppl A):A25–30
   PubMed Web of Science ®Google Scholar
• Emre M, Farlow M, Bullock R, et al. Cholinesterase inhibitors in Alzheimer’s disease: a consensus view on managing treatment failure. Prim Care Psych 2003;9(1), in press
   Web of Science ®Google Scholar
• Vellone E, Micci F, Sansoni J, et al. The lived experience of family member caring for a person affected by Alzheimer’s disease: preliminary results [Italian]. Prof Inferm 2000;53:132–41
   PubMedGoogle Scholar
• Vellone E, Piras G, Sansoni J. Stress, anxiety, and depression among caregivers of patients with Alzheimer’s disease [Italian]. Ann Ig 2002;14:223–32
   PubMedGoogle Scholar
• Lamb HM, Goa KL. Rivastigmine. A pharmacoeconomic review of its use in Alzheimer’s disease. Pharmacoeconomics 2001;19:303–18
   PubMed Web of Science ®Google Scholar
• Fenn P, Gray A. Estimating long term cost savings from treatment of Alzheimer’s disease. Pharmacoeconomics 1999;2:165–74
   Web of Science ®Google Scholar
• Caro JJ, Getsios D, Migliaccio-Walle K, et al. A comparison of pharmacoeconomic outcomes with galantamine, rivastigmine and donepezil. Neurology 2002;53(Suppl 3):A135
   Google Scholar
• Lyseng-Williamson KA, Plosker GL. Galantamine: a pharmacoeconomic review of its use in Alzheimer’s disease. Pharmacoeconomics 2002;20:919–42
   PubMed Web of Science ®Google Scholar
• Foster RH, Plosker GL. Donepezil. Pharmacoeconomic implications of therapy. Pharmacoeconomics 1999;16:99–114
   PubMed Web of Science ®Google Scholar
• Folstein MF, Folstein SE, McHugh PR. ‘Mini-Mental State’ a practical method for grading the cognitive state of patients for the clinician. J Psychiatric Res 1975;12:189–98
   PubMed Web of Science ®Google Scholar
• Pfeffer RI, Kurosaki TT, Harrah CH Jr, et al. Measurement of functional activities in older adults in the community. J Gerontol 1982;37:323–9
   PubMed Web of Science ®Google Scholar